PharmEnable Therapeutics

PharmEnable is a Cambridge-based drug discovery company developing novel small molecule therapeutics for targets that are inaccessible to biologics, including intracellular targets and those behind the blood-brain barrier.

Its proprietary platform integrates AI and advanced medicinal chemistry to explore undercharted chemical space, generating highly complex, three-dimensional molecules with improved selectivity.

PharmEnable maintains a wholly-owned oncology pipeline and conducts co-discovery partnerships with pharma and biotech partners across oncology and neurological disease.